Reported Saturday, Mirum Pharmaceuticals' LIVMARLI Data Presented At ESPGHAN, Featuring Key Findings On ALGS And PFIC
Portfolio Pulse from Benzinga Newsdesk
Mirum Pharmaceuticals presented data at ESPGHAN showing significant improvements in patients with PFIC and ALGS treated with LIVMARLI. Key findings include reductions in pruritus severity, serum bile acid levels, and bilirubin, as well as decreased use of concomitant medications.
May 20, 2024 | 6:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mirum Pharmaceuticals presented positive data on LIVMARLI at ESPGHAN, showing significant improvements in patients with PFIC and ALGS. This includes reductions in pruritus severity, serum bile acid levels, and bilirubin, as well as decreased use of concomitant medications.
The positive data presented at ESPGHAN highlights the efficacy of LIVMARLI in treating PFIC and ALGS, which could lead to increased adoption and sales. This is likely to have a positive short-term impact on Mirum Pharmaceuticals' stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100